MRI correlates of disability progression in patients with CIS over 48 months

Background Gray matter (GM) and white matter (WM) pathology has an important role in disease progression of multiple sclerosis (MS). Objectives To investigate the association between the development of GM and WM pathology and clinical disease progression in patients with clinically isolated syndrome (CIS). Methods This prospective, observational, 48-month follow-up study examined 210 CIS patients treated with 30 µg of intramuscular interferon beta-1a once a week. MRI and clinical assessments were performed at baseline, 6, 12, 24, 36 and 48 months. Associations between clinical worsening [24-weeks sustained disability progression (SDP) and occurrence of a second clinical attack] and longitudinal changes in lesion accumulation and brain atrophy progression were investigated by a mixed-effect model analysis after correction for multiple comparisons. Results SDP was observed in 32 (15.2%) CIS patients, while 146 (69.5%) were stable and 32 (15.2%) showed sustained disability improvement. 112 CIS patients (53.3%) developed clinically definite MS (CDMS). CIS patients who developed SDP showed increased lateral ventricle volume (p < .001), and decreased GM (p = .011) and cortical (p = .001) volumes compared to patients who remained stable or improved in disability. Converters to CDMS showed an increased rate of accumulation of number of new/enlarging T2 lesions (p < .001), decreased whole brain (p = .007) and increased lateral ventricle (p = .025) volumes. Conclusions Development of GM pathology and LVV enlargement are associated with SDP. Conversion to CDMS in patients with CIS over 48 months is dependent on the accumulation of new lesions, LVV enlargement and whole brain atrophy progression.

[1]  Elizabeth Fisher,et al.  Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications , 2005, Multiple sclerosis.

[2]  J. LERE BOULLET,et al.  [Brain atrophy]. , 1954, La Revue du praticien.

[3]  R. Zivadinov,et al.  Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis? , 2012, BMC Neurology.

[4]  M. Battaglini,et al.  Cortical lesions in radiologically isolated syndrome , 2011, Neurology.

[5]  R. Henry,et al.  Regional grey matter atrophy in clinically isolated syndromes at presentation , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  M. Dwyer,et al.  Cine cerebrospinal fluid imaging in multiple sclerosis , 2012, Journal of magnetic resonance imaging : JMRI.

[7]  E. Portaccio,et al.  Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study , 2009, Multiple sclerosis.

[8]  Turi O. Dalaker,et al.  Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[10]  À. Rovira,et al.  Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.

[11]  M. Ramanathan,et al.  Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes , 2013, Journal of Neuroimmunology.

[12]  Robert Zivadinov,et al.  Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model , 2014, NeuroImage.

[13]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[14]  M. Ramanathan,et al.  Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study , 2013, PloS one.

[15]  M. Ramanathan,et al.  Lipid pro fi les are associated with lesion formation over 24 months in interferon-β treated patients following the fi rst demyelinating event , 2013 .

[16]  Ondrej Dolezal,et al.  Clinical correlates of grey matter pathology in multiple sclerosis , 2012, BMC Neurology.

[17]  Bertrand Audoin,et al.  Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging , 2011, PloS one.

[18]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[19]  Dana Horakova,et al.  Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.

[20]  David H. Miller,et al.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.

[21]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[22]  Chiara Romualdi,et al.  Cortical atrophy is relevant in multiple sclerosis at clinical onset , 2007, Journal of Neurology.

[23]  J. Ranjeva,et al.  Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  J. L. Cox,et al.  Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case–control study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[25]  Simon Hametner,et al.  Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.

[26]  M. Dwyer,et al.  Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.

[27]  Peter K. Stys,et al.  Gray matter pathology in (chronic) MS: Modern views on an early observation , 2009, Journal of the Neurological Sciences.

[28]  G. Comi,et al.  Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[29]  J. Ranjeva,et al.  Individual voxel‐based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis , 2010, Journal of magnetic resonance imaging : JMRI.

[30]  B. Healy,et al.  Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis , 2013, Multiple sclerosis international.

[31]  M. Dwyer,et al.  Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.

[32]  C. Guttmann,et al.  Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome , 2013, Genes and Immunity.

[33]  R. Rudick,et al.  Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.

[34]  T. Winder Lipid profiles. , 1994, British journal of hospital medicine.

[35]  M. Calabrese,et al.  Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.

[36]  Marco Bozzali,et al.  Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. , 2010, Radiology.

[37]  C. Lucchinetti,et al.  Meningeal and cortical grey matter pathology in multiple sclerosis , 2012, BMC Neurology.

[38]  J Sastre-Garriga,et al.  Clinical impact of early brain atrophy in clinically isolated syndromes , 2013, Multiple sclerosis.

[39]  M. Calabrese,et al.  The predictive value of gray matter atrophy in clinically isolated syndromes , 2011, Neurology.

[40]  S. Hussein,et al.  Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years , 2013, American Journal of Neuroradiology.

[41]  P. Matthews,et al.  Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.

[42]  E. Radue,et al.  Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a , 2005, Neurology.

[43]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[44]  Massimo Filippi,et al.  A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes , 2008, NeuroImage.

[45]  M. Ramanathan,et al.  Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[46]  M. Calabrese,et al.  Low degree of cortical pathology is associated with benign course of multiple sclerosis , 2013, Multiple sclerosis.

[47]  F. Barkhof,et al.  A three-year, multi-parametric MRI study in patients at presentation with CIS , 2008, Journal of Neurology.

[48]  M. Battaglini,et al.  Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis , 2011, PloS one.

[49]  P. Matthews,et al.  Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability , 2011, Multiple sclerosis.

[50]  Stephen M. Smith,et al.  A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.